Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
Globe Newswire•01/10/2026•11:35 ET
0
Key Highlights
- ➤Ubamatamab (REGN) delivered 73% objective response rate at 800 mg monotherapy
- ➤800 mg ubamatamab produced 9-month median duration of response
- ➤800 mg ubamatamab achieved 11-month median progression-free survival
- ➤Regeneron (REGN) plans confirmatory randomized Phase 3 LGSOC trial
- ➤Regeneron (REGN) is enrolling potentially registrational LGSOC cohort
Expert Statements
Israel Lowy, Clinical Development Unit Head, Oncology, at Regeneron
“The high rate of durable responses observed thus far with ubamatamab in low-grade serous ovarian cancer, without requiring biomarker selection, are highly encouraging and reinforce our excitement about MUC16 as a new therapeutic target in this difficult-to-treat disease.”
Israel Lowy, Clinical Development Unit Head, Oncology, at Regeneron
“This initial clinical evidence highlights the potential of our bispecific approach to bring a differentiated and first-in-class treatment option to patients in need.”
Israel Lowy, Clinical Development Unit Head, Oncology, at Regeneron
“We are pleased with the safety profile of the drug as well, and are eager to build on these findings through our ongoing trial and planned confirmatory Phase 3 trial.”
LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy
Results presented in a late-breaking plenary session at IGCS demonstrated a 73% objective response rate and 11-month median progression-free survival in 11 patients with recurrent and heavily pre-treated LGSOC treated with the highest dose of ubamatamab in the trial
Get started
Create a free account to read the full story.